DK1212317T3 - Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser - Google Patents

Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser

Info

Publication number
DK1212317T3
DK1212317T3 DK00943839T DK00943839T DK1212317T3 DK 1212317 T3 DK1212317 T3 DK 1212317T3 DK 00943839 T DK00943839 T DK 00943839T DK 00943839 T DK00943839 T DK 00943839T DK 1212317 T3 DK1212317 T3 DK 1212317T3
Authority
DK
Denmark
Prior art keywords
osteoporosis
treatment
indole derivatives
indole
derivatives
Prior art date
Application number
DK00943839T
Other languages
Danish (da)
English (en)
Inventor
Carlo Farina
Stefania Gagliardi
Pietro A T Novella
Original Assignee
Nikem Research Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikem Research Srl filed Critical Nikem Research Srl
Application granted granted Critical
Publication of DK1212317T3 publication Critical patent/DK1212317T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
DK00943839T 1999-06-18 2000-06-16 Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser DK1212317T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914371.1A GB9914371D0 (en) 1999-06-18 1999-06-18 Novel compounds

Publications (1)

Publication Number Publication Date
DK1212317T3 true DK1212317T3 (da) 2005-01-24

Family

ID=10855696

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00943839T DK1212317T3 (da) 1999-06-18 2000-06-16 Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser

Country Status (30)

Country Link
US (2) US6787550B1 (fr)
EP (1) EP1212317B1 (fr)
JP (1) JP2003503490A (fr)
KR (1) KR100701109B1 (fr)
CN (1) CN1179960C (fr)
AR (1) AR024390A1 (fr)
AT (1) ATE276245T1 (fr)
AU (1) AU768726B2 (fr)
BR (1) BR0011708A (fr)
CA (1) CA2376657A1 (fr)
CO (1) CO5200757A1 (fr)
CZ (1) CZ301697B6 (fr)
DE (1) DE60013859T2 (fr)
DK (1) DK1212317T3 (fr)
ES (1) ES2226870T3 (fr)
GB (1) GB9914371D0 (fr)
GC (1) GC0000341A (fr)
HK (2) HK1048468B (fr)
HU (1) HUP0202049A3 (fr)
IL (2) IL147012A0 (fr)
MX (1) MXPA01013277A (fr)
MY (1) MY129425A (fr)
NO (1) NO322313B1 (fr)
NZ (1) NZ516131A (fr)
PL (1) PL352964A1 (fr)
PT (1) PT1212317E (fr)
TR (1) TR200103683T2 (fr)
TW (1) TWI248440B (fr)
WO (1) WO2001002388A1 (fr)
ZA (1) ZA200200177B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2530235T3 (es) 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
BRPI0412694A (pt) * 2003-07-15 2006-10-03 Smithkline Beecham Corp compostos
ITMI20040875A1 (it) * 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici utili per il trattamento della resistenza agli agenti antitumorali
MX2007003040A (es) 2004-09-17 2007-08-02 Idenix Pharmaceuticals Inc Fosfoindoles como inhibidores de vih.
WO2006041874A2 (fr) * 2004-10-04 2006-04-20 Myriad Genetics, Inc. Composes destines a la maladie d'alzheimer
US7833805B2 (en) * 2004-10-21 2010-11-16 University Of Cincinnati Selectively permeable membranes on porous substrates
JP5070050B2 (ja) 2005-07-20 2012-11-07 正徳 染井 トリプトファン誘導体及びその用途
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
EP1915341A2 (fr) 2005-08-15 2008-04-30 Irm, Llc Composés et compositions en tant que mimétiques de tpo
EP1779848A1 (fr) * 2005-10-28 2007-05-02 Nikem Research S.R.L. Inhibiteurs de la V-ATPase pour le traitement des maladies inflammatoires et autoimmunes
EP1779849A1 (fr) 2005-10-28 2007-05-02 Nikem Research S.R.L. inhibiteurs de V-ATPase pour le traitement du choc septique
CN101374414A (zh) 2006-01-25 2009-02-25 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
EP1976377A4 (fr) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp Composés destinés au traitement des troubles du métabolisme
WO2007092729A2 (fr) 2006-02-02 2007-08-16 Wellstat Therapeutics Corporation Composes pour le traitement de troubles metaboliques
WO2008008895A1 (fr) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Agonistes gpr119 destinés au traitement du diabète et des troubles associés
AU2007305447A1 (en) 2006-09-29 2008-04-10 Idenix Pharmaceuticals, Inc Enantiomerically pure phosphoindoles as HIV inhibitors
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
ES2806691T3 (es) 2009-02-16 2021-02-18 Nogra Pharma Ltd Compuestos de alquilamido y usos de los mismos
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
EA023258B1 (ru) 2010-09-08 2016-05-31 Бристол-Маерс Сквибб Компани 1,4-пиперазиновые производные в качестве средства от вирусного гриппа
WO2012045451A1 (fr) 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Nouveau traitement thérapeutique de maladies dépendantes de la progranuline
US20120142627A1 (en) * 2010-12-06 2012-06-07 Emory University Monophosphate prodrugs of dapd and analogs thereof
CN104254327A (zh) 2012-02-09 2014-12-31 诺格拉制药有限公司 治疗纤维化的方法
MX2014012652A (es) 2012-04-18 2014-11-25 Nogra Pharma Ltd Metodo de tratamiento de la intolerancia a la lactosa.
CN113825739A (zh) 2019-02-08 2021-12-21 诺格拉制药有限公司 制备3-(4’-氨基苯基)-2-甲氧基丙酸及其类似物和中间体的方法
CN113024432A (zh) * 2019-12-24 2021-06-25 上海科胜药物研发有限公司 一种氨磺必利药典杂质的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
EP0802902A1 (fr) * 1995-01-10 1997-10-29 Smithkline Beecham S.p.A. Derives indole utiles dans le traitement de l'osteoporose
PL330994A1 (en) 1996-07-09 1999-06-21 Smithkline Beecham Spa Indolic derivatives for use in treating osteoporosis
BR9814403A (pt) * 1997-12-24 2000-10-10 Smithkline Beecham Lab "derivados do indol úteis para o tratamento, entre outros, de osteoporose"

Also Published As

Publication number Publication date
NO322313B1 (no) 2006-09-11
PT1212317E (pt) 2005-02-28
US6787550B1 (en) 2004-09-07
TR200103683T2 (tr) 2003-01-21
ES2226870T3 (es) 2005-04-01
HUP0202049A2 (hu) 2002-11-28
ATE276245T1 (de) 2004-10-15
CO5200757A1 (es) 2002-09-27
CZ301697B6 (cs) 2010-05-26
KR20020025079A (ko) 2002-04-03
CN1179960C (zh) 2004-12-15
IL147012A0 (en) 2002-08-14
NO20016149L (no) 2001-12-17
NZ516131A (en) 2003-10-31
HK1048468B (zh) 2005-07-29
DE60013859D1 (de) 2004-10-21
CA2376657A1 (fr) 2001-01-11
MXPA01013277A (es) 2002-06-04
AR024390A1 (es) 2002-10-02
HK1049164A1 (zh) 2003-05-02
GC0000341A (en) 2007-03-31
MY129425A (en) 2007-03-30
IL147012A (en) 2007-06-03
JP2003503490A (ja) 2003-01-28
AU5816500A (en) 2001-01-22
EP1212317B1 (fr) 2004-09-15
CN1370159A (zh) 2002-09-18
WO2001002388A1 (fr) 2001-01-11
PL352964A1 (en) 2003-09-22
NO20016149D0 (no) 2001-12-17
GB9914371D0 (en) 1999-08-18
HK1048468A1 (en) 2003-04-04
US20040235930A1 (en) 2004-11-25
AU768726B2 (en) 2004-01-08
DE60013859T2 (de) 2005-09-29
CZ20014496A3 (cs) 2002-07-17
KR100701109B1 (ko) 2007-03-29
EP1212317A1 (fr) 2002-06-12
HUP0202049A3 (en) 2003-12-29
TWI248440B (en) 2006-02-01
BR0011708A (pt) 2002-05-21
ZA200200177B (en) 2003-09-23

Similar Documents

Publication Publication Date Title
DK1212317T3 (da) Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser
DK1021410T3 (da) Prostaglandinagonister og deres anvendelse til behandling af knogletilstande
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
NO20013393D0 (no) Brönnsementeringsfremgangsmåter og sammensetninger
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20015362D0 (no) Heterocyklisk substituerte benzimidazoler, deres fremstilling og anvendelse derav
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
DK1392292T3 (da) Pyranoindazoler og deres anvendelse til behandling af glaukom
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
DK1216046T3 (da) Hidtil ukendt kombination af loteprednol og antihistaminer
DK1228028T3 (da) Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
DK1432417T3 (da) Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
DK1143997T3 (da) Tumor nekrose faktor antagonister og deres anvendelse i behandling af endometriosis
DK1341786T3 (da) Substituerede derivater af aminofuran-2-yl-eddikesyre og aminothien-2-yl-eddikesyre og anvendelsen deraf til behandling af migræner og smerte
NO20020031D0 (no) Dihydrobenzodiazepiner og deres anvendelse ved behandling av dyslipidemi
IS2607B (is) Afleiður tryptamíns og hliðstæð efnasambönd ásamt lyfjaforskriftum þeirra
NO20030547L (no) Azabicykliske derivater og deres terapeutiske anvendelse